These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23153525)

  • 1. Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.
    Le Pogam C; Krief P; Beurlet S; Soulié A; Balitrand N; Cassinat B; Cavé H; Kosmider O; Setterblad N; Leboeuf C; Sarda-Mantel L; Hervatin F; Merlet P; Noguera ME; Janin A; Pla M; Fontenay M; Adès L; Fenaux P; Chomienne C; Padua RA; Omidvar N
    Leuk Res; 2013 Mar; 37(3):312-9. PubMed ID: 23153525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
    Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA
    Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.
    Gorombei P; Guidez F; Ganesan S; Chiquet M; Pellagatti A; Goursaud L; Tekin N; Beurlet S; Patel S; Guerenne L; Le Pogam C; Setterblad N; de la Grange P; LeBoeuf C; Janin A; Noguera ME; Sarda-Mantel L; Merlet P; Boultwood J; Konopleva M; Andreeff M; West R; Pla M; Adès L; Fenaux P; Krief P; Chomienne C; Omidvar N; Padua RA
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
    Beurlet S; Omidvar N; Gorombei P; Krief P; Le Pogam C; Setterblad N; de la Grange P; Leboeuf C; Janin A; Noguera ME; Hervatin F; Sarda-Mantel L; Konopleva M; Andreeff M; Tu AW; Fan AC; Felsher DW; Whetton A; Pla M; West R; Fenaux P; Chomienne C; Padua RA
    Blood; 2013 Oct; 122(16):2864-76. PubMed ID: 23943652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein.
    Yoneda-Kato N; Fukuhara S; Kato J
    Oncogene; 1999 Jun; 18(25):3716-24. PubMed ID: 10391679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes.
    Boudard D; Vasselon C; Berthéas MF; Jaubert J; Mounier C; Reynaud J; Viallet A; Chautard S; Guyotat D; Campos L
    Am J Hematol; 2002 Jun; 70(2):115-25. PubMed ID: 12111784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins.
    Parker JE; Fishlock KL; Mijovic A; Czepulkowski B; Pagliuca A; Mufti GJ
    Br J Haematol; 1998 Dec; 103(4):1075-82. PubMed ID: 9886323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of immunohistochemical results of the ras oncogene product p21 in myelodysplastic syndromes.
    Kalmantis T; Kalmanti M; Vassilaki M; Spandidos DA
    Anticancer Res; 1993; 13(4):1103-6. PubMed ID: 8352532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes.
    Invernizzi R; Pecci A; Bellotti L; Ascari E
    Leuk Lymphoma; 2001 Jul; 42(3):481-9. PubMed ID: 11699413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of apoptosis regulatory genes expression in the bone marrow (BM) of adult de novo myelodysplastic syndromes (MDS).
    Economopoulou C; Pappa V; Kontsioti F; Papageorgiou S; Kapsimali V; Papasteriadi C; Economopoulou P; Papageorgiou E; Dervenoulas J; Economopoulos T
    Leuk Res; 2008 Jan; 32(1):61-9. PubMed ID: 17597205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis.
    Lepelley P; Soenen V; Preudhomme C; Merlat A; Cosson A; Fenaux P
    Leukemia; 1995 Apr; 9(4):726-30. PubMed ID: 7723410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression.
    Davis RE; Greenberg PL
    Leuk Res; 1998 Sep; 22(9):767-77. PubMed ID: 9716007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis in the myelodysplastic syndromes.
    Westwood NB; Mufti GJ
    Curr Hematol Rep; 2003 May; 2(3):186-92. PubMed ID: 12901339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What does apoptosis have to do with clinical features in myelodysplastic syndrome?
    Ramos F; Fuertes-Núñez M; Suárez-Vilela D; Fernández-López A
    Haematologica; 2002 Apr; 87(4):381-91. PubMed ID: 11940482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
    Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
    Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-x(S) can form homodimers and heterodimers and its apoptotic activity requires localization of Bcl-x(S) to the mitochondria and its BH3 and loop domains.
    Lindenboim L; Borner C; Stein R
    Cell Death Differ; 2001 Sep; 8(9):933-42. PubMed ID: 11526448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.